Ocuphire Pharma terminates CEO Mina Sooch, appoints Rick Rodgers as interim CEO

Opus Genetics, Inc.

On April 19, 2023, terminated CEO Mina Sooch; Richard Rodgers appointed interim President & CEO.
Rodgers receives $40,000 monthly salary and 50,000 RSUs vesting in 12 months.
Rodgers resigned from Audit and Compensation Committees; Gallagher and Manuso filled vacancies.
Interim CEO to focus on APX3330 Phase 3 path and Nyxol NDA with PDUFA in September 2023.
Company retained executive search firm to identify a permanent CEO.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Richard Rodgers

interim President and Chief Executive Officer

IRD · Opus Genetics, Inc.

Effective: 2023-04-19
Filed: April 21, 2023, 7:59 PM ET

On April 19, 2023, the Board of Directors o f the Company (the “ Board ”) appointed Richard Rodgers as the Company’s interim President and Chief Executive Officer effective as of April 19 , 2023.

Departed

Mina Sooch

President and Chief Executive Officer

IRD · Opus Genetics, Inc.

Effective: 2023-04-19
Successor: Richard Rodgers
Filed: April 21, 2023, 7:59 PM ET

On April 19, 2023, Ocuphire Pharma, Inc. (the “ Company ”) terminated the employment of Mina Sooch, the President and Chief Executive Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Rodgers was appointed as interim President and Chief Executive Officer at Opus Genetics, Inc..

Action: appointed
Role: interim President and Chief Executive Officer

Exact text from the filing

On April 19, 2023, the Board of Directors o f the Company (the “ Board ”) appointed Richard Rodgers as the Company’s interim President and Chief Executive Officer effective as of April 19 , 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mina Sooch was terminated as President and Chief Executive Officer at Opus Genetics, Inc..

Action: terminated
Role: President and Chief Executive Officer

Exact text from the filing

On April 19, 2023, Ocuphire Pharma, Inc. (the “ Company ”) terminated the employment of Mina Sooch, the President and Chief Executive Officer of the Company.

View on SEC.gov

Opus Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-019505

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.